(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039172 A1

(51) International Patent Classification:
*C07D 413/12* (2006.01) *A61K 31/4245* (2006.01)

(21) International Application Number:
PCT/EP2006/009298

(22) International Filing Date:
26 September 2006 (26.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05021235.6 29 September 2005 (29.09.2005) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS DEUTSCHLAND GMBH** [DE/DE]; Brüningstrasse 50, 65929 Frankfurt am Main (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BERNARDELLI, Patrick** [FR/FR]; c/o Aventis Pharma, 13, Quai Jules Guesde, 94403 Vitry-Sur-Seine Cedex (FR). **KEIL, Stefanie** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **URMANN, Matthias** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **MATTER, Hans** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WENDLER, Wolfgang** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **GLIEN, Maike** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **CHANDROSS, Karen** [US/US]; 13 Staudt Ct, Somerset, NJ 08873 (US). **LEE, Jan** [US/US]; Box 230 Pluckemin Park, Pluckemin, NJ 07978 (US). **TERRIER, Corinne** [FR/FR]; c/o Aventis Pharma, 13 Quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex (FR). **MINOUX, Hervé** [FR/FR]; c/o Aventis Pharma, 13 Quai Jules Guesde, F-94403 Vitry-sur-Seine Cedex (FR).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) **Title:** PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS




(I)

(57) **Abstract:** The invention relates to phenyl-1,2,4-oxadiazolone derivatives with phenyl group and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta agonist activity. What is described are compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

WO 2007/039172 A1